title: In vitro characterization of a sustained-release formulation for enfuvirtide.
abstract: Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.
authors.affiliation: Qrono, Inc., Pittsburgh, Pennsylvania, USA.
authors.forename: Sam N
authors.initials: SN
authors.lastname: Rothstein
authors.forename: Kelly D
authors.initials: KD
authors.lastname: Huber
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sluis-Cremer
authors.forename: Steven R
authors.initials: SR
authors.lastname: Little
mesh_terms: D055252:Cell-Derived Microparticles / Q000648:ultrastructure; D003692:Delayed-Action Preparations; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D010446:Peptide Fragments / Q000008:administration & dosage*
chemical_list: D003692:Delayed-Action Preparations; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide